Y mAbs Therapeutics (YMAB)YMAB

Y mAbs Therapeutics: A Comprehensive Overview

Company Profile

History and Background:

Y mAbs Therapeutics, Inc. (YMAB) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibody therapeutics for the treatment of cancer. Founded in 2012 and headquartered in New York, NY, the company leverages its proprietary Y-Body™ platform to generate bispecific and multispecific antibody therapeutics with enhanced efficacy and safety profiles.

Core Business Areas:

YMAB's core business areas encompass:

• Discovery and development of novel bispecific and multispecific antibody therapeutics: Leveraging its Y-Body™ platform, the company focuses on developing therapies targeting various cancer types, including hematologic malignancies and solid tumors.
• Clinical development of lead candidates: Y mAbs currently has several ongoing clinical trials for its lead candidates, including OMB157, a bispecific antibody targeting CD3 and CD123 for the treatment of acute myeloid leukemia (AML).
• Seeking strategic partnerships: Y mAbs actively seeks collaborations and partnerships to accelerate the development and commercialization of its therapeutic candidates.

Leadership and Corporate Structure:

• Co-founder, Chairman and CEO: Thomas Gad, Ph.D.
• Chief Medical Officer: David Hong, M.D.
• Chief Scientific Officer: Jonathan E. Rosenberg, Ph.D.
• Chief Financial Officer: Yi (Frank) Zhong

Y mAbs operates with a Board of Directors and an executive leadership team, overseeing the company's strategic direction and operational execution.

Top Products and Market Share:

Lead candidate: OMB157

• Description: A bispecific antibody targeting CD3 and CD123 for the treatment of AML.
• Market share: Currently in Phase 1/2 clinical trials, OMB157 does not yet hold a market share.
• Product performance and market reception: Early data from clinical trials show promising efficacy and safety profiles.

Other notable candidates:

• OMB110: A bispecific antibody targeting CD3 and EGFR for the treatment of head and neck squamous cell carcinoma (HNSCC).
• OMB234: A bispecific antibody targeting CD3 and PSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

These candidates are also in early-stage clinical development and do not yet hold market share.

Competitive landscape:

Y mAbs faces competition from other companies developing bispecific and multispecific antibody therapeutics for cancer treatment, including:

• Amgen (AMGN): Blinatumomab (Blincyto)
• Roche (RHHBY): Mosunetuzumab (Lunsumio)
• Macrogenics (MGNX): MGD013

Y mAbs differentiates itself through its proprietary Y-Body™ platform, which allows for the development of highly potent and specific antibodies with enhanced tumor targeting and reduced toxicity.

Total Addressable Market:

The global market for cancer immunotherapy is expected to reach $342.7 billion by 2027, growing at a CAGR of 15.7% from 2022. The US market represents a significant portion of this global market.

Financial Performance:

Revenue:

Y mAbs is currently a pre-commercial stage company with no marketed products. As a result, its revenue is primarily derived from research and development collaborations and grants.

Net income:

Y mAbs has not yet achieved profitability. The company's net loss in 2022 was $54.3 million, compared to $40.6 million in 2021.

Profit margins and EPS:

Y mAbs's gross margin in 2022 was -94.7%, indicating that the cost of developing its products exceeds its revenue. The company's EPS for 2022 was -$1.71.

Cash flow and balance sheet:

As of December 31, 2022, Y mAbs had $240.7 million in cash and cash equivalents. The company's total assets were $275.3 million, and its total liabilities were $23.2 million.

Dividends and Shareholder Returns:

Dividend history:

Y mAbs does not currently pay dividends to shareholders.

Shareholder returns:

Y mAbs's stock has experienced significant volatility in recent years. Over the past year, the stock price has declined by approximately 30%. However, over a longer time horizon, the stock has experienced significant growth. From its IPO in 2020 to its peak in 2021, the stock price increased by over 800%.

Growth Trajectory:

Historical growth:

Y mAbs has experienced rapid growth in recent years. The company's revenue increased from $1.2 million in 2020 to $12.7 million in 2022. This growth is primarily driven by the company's ongoing clinical trials and research and development collaborations.

Future projections:

Analysts expect Y mAbs to continue experiencing significant growth in the coming years. The company is expected to generate $23.8 million in revenue in 2023 and $61.6 million in 2024. This growth is expected to be driven by the potential commercialization of its lead candidate, OMB157.

Recent product launches and strategic initiatives:

Y mAbs has recently initiated several strategic initiatives to drive growth, including:

• Initiating a Phase 1/2 clinical trial for OMB157 in combination with chemotherapy for the treatment of AML.
• Expanding its research and development collaborations with leading academic institutions and pharmaceutical companies.
• Advancing its manufacturing capabilities to prepare for potential commercialization.

Market Dynamics:

Industry overview:

The development of bispecific and multispecific antibody therapeutics is a rapidly growing field with significant potential to improve cancer treatment outcomes. The market is characterized by intense competition and rapid technological advancements.

Y mAbs's positioning:

Y mAbs is well-positioned within this competitive market due to its proprietary Y-Body™ platform and promising clinical pipeline. The company's focus on developing highly potent and specific antibodies with enhanced tumor targeting and reduced toxicity differentiates it from its competitors.

Competitors:

Key competitors in the bispecific and multispecific antibody therapeutics market for cancer treatment include:

• Amgen (AMGN): Blinatumomab (Blincyto)
• Roche (RHHBY): Mosunetuzumab (Lunsumio)
• Macrogenics (MGNX): MGD013
• AbbVie (ABBV): Telitacicept (EMPA)
• Pfizer (PFE): AMG 509

Potential Challenges and Opportunities:

Key challenges:

• Clinical trial success: Y mAbs's future success is contingent upon the successful completion of its clinical trials and regulatory approval of its product candidates.
• Competition: The company faces intense competition from established pharmaceutical companies and other biotechnology companies developing bispecific and multispecific antibody therapeutics.
• Manufacturing and commercialization: Y mAbs will need to overcome significant challenges to scale up its manufacturing capabilities and successfully commercialize its products.

Key opportunities:

• Significant unmet medical need: There is a significant unmet medical need for new and effective treatments for cancer. Y mAbs's product candidates have the potential to address this need and improve patient outcomes.
• Strategic partnerships: Y mAbs can leverage strategic partnerships to accelerate the development and commercialization of its product candidates.
• Technological advancements: The company can continue to invest in its Y-Body™ platform and other technologies to maintain its competitive edge.

Recent Acquisitions:

Y mAbs has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI-based fundamental analysis, Y mAbs receives a rating of 7 out of 10. This rating is supported by the company's promising clinical pipeline, strong leadership team, and significant growth potential. However, the company's financial performance and competitive landscape pose some risks that investors should consider.

Sources and Disclaimers:

The information presented in this overview was compiled from the following sources:

• Y mAbs Therapeutics, Inc. website
• SEC filings
• Market research reports
• Industry news articles

This overview is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.